TauRx Pharmaceuticals Ltd.

TauRx Therapeutics was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases based on its technology platform. The TauRx team includes highly skilled and internationally recognised pharmaceutical experts in drug discovery and development. The company’s Tau Aggregation Inhibitors (TAIs) include rember® and LMTX®, the second-generation drug that is being studied in Phase 3 clinical trials in Alzheimer’s and FTD. TauRx is headquartered in Singapore with primary research facilities in Aberdeen, Scotland.